News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
Clinical - Post-Approval (Research/Post Marketing/Phase IV)
Eisai Inc. (ESALF.PK) And Arena Pharmaceuticals, Inc. (ARNA) Report Results Of An Investigational Pilot Study Of Coadministration Of Lorcaserin Hcl And Phentermine Hcl 10/29/2014
Pfizer (PFE)’s PRISTIQ® (Desvenlafaxine) Demonstrates Low Potential For Sexual Dysfunction In Adults With Major Depressive Disorder 10/29/2014
Regeneron (REGN)'s EYLEA® Tops Rivals In Study 10/20/2014
Roche (RHHBY), Merck & Co. (MRK) Extend Immunotherapy Battle To Breast Cancer 10/17/2014
Celgene International Sárl (CELG) Release: Oral OTEZLA® (Apremilast) Data Presented At EADV Show Improved Measures Of Health-Related Quality Of Life And Work Productivity In Patients With Moderate To Severe Plaque Psoriasis 10/10/2014
Celgene International Sárl (CELG) Release: New Analyses Of Oral OTEZLA® (Apremilast) Presented At EADV Show Efficacy In Difficult-To-Treat Areas Of Moderate To Severe Plaque Psoriasis 10/10/2014
Vertex Pharmaceuticals (MA) (VRTX) Reviews Recent Progress And Announces Upcoming Milestones In The Development Of Multiple Combinations Of Medicines That Target The Underlying Cause Of Cystic Fibrosis 10/9/2014
Celgene International Sárl (CELG) To Present Long-Term Efficacy And Safety Data On Oral OTEZLA® (Apremilast) In Plaque Psoriasis And Psoriatic Arthritis At European Academy Of Dermatology And Venereology Congress 10/7/2014
Pfizer (PFE)'s Lung Cancer Drug Xalkori Effective In Rare Gene Trial 9/30/2014
Genentech (RHHBY)'s New Breast Cancer Drug Greatly Extends Survival Rates 9/30/2014
Synapse Biomedical Announces The Early Completion Of Enrollment In The FDA Post Approval Study For ALS Patients 9/30/2014
Janssen Pharmaceutical Inc. Release: ZYTIGA®* Plus Prednisone Demonstrates Statistically Significant Overall Survival In Men With Advanced Prostate Cancer Prior To Chemotherapy 9/29/2014
Daiichi Sankyo, Inc. (4568.t) Receives Approval For Additional Indications Of LIXIANA® (Edoxaban) In Japan 9/26/2014
Repros Therapeutics Inc. (RPRX) Release: Androxal® Second Pivotal Study Achieves Superiority In Top Line Analysis For Both Co-Primary Endpoints Versus Marketed Topical Gel In The Treatment Of Secondary Hypogonadism 9/26/2014
EPIRUS Biopharmaceuticals Announces Positive 58 Week Follow Up Data For BOW015 For Treatment Of Rheumatoid Arthritis 9/23/2014
Parenteral Drug Association Launches Effort To Harmonize Global Post-Approval Changes Protocols 9/22/2014
Zogenix, Inc. (ZGNX) Release: New Data Shows Zohydro® ER Reduced Pain And Improved Function In People With Chronic Pain 9/18/2014
Janssen-Cilag International NV (JNJ) Release: Results From Head-To-Head Studies Of INVOKANA® (Canagliflozin) Versus JANUVIA (Sitagliptin) Highlight The Importance Of Weight-Change On Quality Of Life And Cost Effectiveness Of Canagliflozin Among People With Type 2 Diabetes 9/17/2014
Vince & Associates Clinical Research Completes Enrollment Of Human Abuse Liability Study For Centanafadine For Adult ADHD 9/16/2014
Study Shows Novo Nordisk A/S (NVO)'s New Diabetes Drug Tresiba Effective And Safe For Children 9/16/2014
Astellas Pharma Inc. (ALPMY) Release: U.S. FDA Approves New Indication For The Use Of XTANDI® (enzalutamide) Capsules For Patients With Metastatic Castration-Resistant Prostate Cancer 9/11/2014
Teva Pharmaceutical Industries Limited (TEVA) Presents New Data Which Demonstrate Reduction Of Injection-Related Adverse Events With The Less Frequent Dosing Of Three-Times-A-Week COPAXONE® (Glatiramer Acetate Injection) 40 Mg Compared To Daily COPAXONE® 20 Mg 9/11/2014
Novartis AG (NVS): Rate Of Brain Shrinkage Faster In Multiple Schlerosis Patients 9/10/2014
Novaliq GmbH Announces Positive Results From Novatears® Observational Study In Mild To Moderate Evaporative Dry Eye Disease 9/10/2014
Sanofi Pasteur (SASY.PA) Release: FDA Approves Use Of Menactra® Vaccine For Booster Immunization Against Potentially Deadly Disease 9/9/2014
Amgen (AMGN), Servier Heart Drug Runs Into Safety Concerns In Major Clinical Study 9/4/2014
The International Myeloma Foundation Says Newly Published Study Confirms Survival Advantage With REVLIMID® And Further Advantages With Continuous Use In Newly Diagnosed Multiple Myeloma Patients Not Eligible For Transplant 9/4/2014
Boehringer Ingelheim Corporation Release: European Society of Cardiology Congress 2014 Hot Line Session: Favourable Effect Of Pradaxa® On Kidney Function Over Time Compared To Warfarin 9/2/2014
Zogenix, Inc. (ZGNX) Release: Zohydro® ER Demonstrates Sustained 12-Hour Pain Relief 9/2/2014
Vifor Pharma Release: CONFIRM-HF Study Demonstrates That Injectafer® (Ferinject®) Improves Exercise Capacity In Patients With Chronic Heart Failure 9/2/2014
MediciNova, Inc. To Initiate Clinical Trial Of MN-166 (Ibudilast) In ALS 8/26/2014
Coherus Biosciences' Biosimilar Meets Primary Endpoint In Pivotal Pharmacokinetic Clinical Study 8/15/2014
FDA Advisory Committee Recommends Approval Of Tiotropium Respimat® For The Maintenance Treatment Of COPD 8/15/2014
Sanofi Pasteur (SASY.PA) Touts Positive Trial Data For Fluzone High-Dose Vaccine 8/14/2014
Pfizer Inc. (PFE) Reports Top-Line Results From Two Placebo-Controlled Studies With Lyrica 8/13/2014
Scientists Retract Narcolepsy Study Linked To GlaxoSmithKline (GSK) Flu Vaccine 8/11/2014
Ampio Pharmaceuticals, Inc. (AMPE) Updates On Positive One-Month Results From Ampion Open Label Study 8/5/2014
Berlin Heart, Inc. Completes Enrollment In The EXCOR® Pediatric Ventricular Assist Device (VAD) Post Approval Study 8/4/2014
Hemispherx Biopharma (HEB)'s Two Drugs, Ampligen® And Alferon® Ranked Highly In Sensitivity Testing Against MERS/SARS Coronaviruses 8/4/2014
Alexion Pharmaceuticals Inc. (ALXN) Release: European Commission Grants Orphan Drug Designation To Soliris® (Eculizumab) For The Treatment Of Patients With Myasthenia Gravis (MG) 8/1/2014
Study Claims Celgene (CELG) Drug Can Drive HIV Out Of Hiding 7/25/2014
CTI BioPharma Expands Access To PIXUVRI® With Approval In Israel And Add-on Reimbursement Status In The Netherlands 7/21/2014
Shire Reports Results From Two Head-To-Head Studies Comparing Vyvanse® With Concerta® In ADHD Study 7/18/2014
Bristol-Myers Squibb Company (BMY) And Pfizer Inc. (PFE) Announce Enrollment Of First Patient In Phase IV EMANATE Trial To Assess Effectiveness And Safety Of Eliquis® (Apixaban) In Patients With NVAF Undergoing Cardioversion 7/17/2014
FDA Grants Astellas Qualified Infectious Disease Product Designation For Isavuconazole For The Treatment Of Invasive Candidiasis 7/16/2014
ACell, Inc. Initiates Post-Market Study Of MatriStem® Pelvic Floor Matrix 7/15/2014
Celgene (CELG)'s OTEZLA® Misses Mark In Phase 3 Spinal Arthritis Study 7/10/2014
Controversial Trial Discovers No Benefit For Expensive The Medicines Company (MDCO) Drug 7/9/2014
Merck & Co., Inc. (MRK)'s Gardasil HPV Vaccine Doesn't Increase Blood Clot Risk 7/9/2014
Merck & Co., Inc. (MRK)'s Januvia Linked To Increase In Heart Failure Hospitalizations 7/8/2014
Sunovion Pharmaceuticals Inc. Announces Data Published In The CHEST Journal From A One-Year, Large Simple Safety Study Evaluating BROVANA® (Arformoterol Tartrate) Inhalation Solution 7/8/2014
Roche (RHHBY) Finds "Serious Flaws" In Recent Study Doubting Tamiflu's Effectiveness 7/1/2014
FDA Grants Breakthrough Therapy Designation To Pradaxa® (Dabigatran Etexilate) Specific Investigational Antidote 6/30/2014
Veloxis Pharmaceuticals A/S (VELO) Release: Envarsus® XR Demonstrates Lower Treatment Failure Rate In African-Americans Compared To Twice-Daily Tacrolimus (Prograf®) 6/30/2014
InDex Pharmaceuticals AB Announces Results From COLLECT, A Clinical Trial Of Kappaproct® In The Treatment Of Moderate To Severe Ulcerative Colitis 6/27/2014
Pacira Pharmaceuticals, Inc. (PCRX) Announces Publication Of Pooled Results From IMPROVE Studies Evaluating Health Economic Benefits Of EXPAREL® 6/26/2014
ImpediMed Inc. Release: International Post-Approval Clinical Trial Commences Ahead Of Schedule 6/26/2014
H. Lundbeck A/S (LUN.CO) Release: New Study Results Demonstrate Brintellix® (Vortioxetine) Is Efficacious In Asian Patients Suffering From Depression 6/26/2014
Raptor Pharmaceutical Inc. (RPTP) Release: Data Published In Journal Of Pediatrics Demonstrated That PROCYSBI® Improved Quality Of Life And Preserved Kidney Function In Cystinosis Patients 6/24/2014
A 4-Week Hepatitis C Cure? Bristol-Myers Squibb Company (BMY) To Test Drugs With Gilead Sciences, Inc. (GILD)'s Sovaldi 6/23/2014
Chelsea Therapeutics, Inc. (CHTP) Release: NORTHERA™ Clinical Trial Data Published in Neurology 6/20/2014
Grafix® Manuscript From Osiris Therapeutics, Inc. (OSIR)’ Multi-Center, Randomized, Controlled Clinical Trial Accepted In Peer-Reviewed Journal 6/19/2014
Alexion Pharmaceuticals Inc. (ALXN) Release: FDA Grants Orphan Drug Designation To Soliris® (Eculizumab) For The Treatment Of Patients With Myasthenia Gravis (MG) 6/17/2014
Takeda Pharmaceutical Co. Ltd. (TKPYY) Release: Results Of A New Study Of Brintellix® (vortioxetine) vs. Escitalopram On Sexual Functioning In Well Treated MDD Patients Experiencing Treatment-Emergent Sexual Dysfunction 6/17/2014
Zealand Pharma  (ZEAL.CO) Provides Summary Of New Clinical Data And Information On Lyxumia® (Lixisenatide) And Lixilan Presented At The American Diabetes Association’s 74th Scientific Sessions 6/17/2014
H. Lundbeck A/S (LUN.CO) Release: Brintellix® Demonstrated A Statistically Significantly Superior Improvement Compared To Escitalopram In Improving Sexual Functioning In Well Treated Patients Suffering From Depression And Experiencing Treatment-Emergent Sexual Dysfunction 6/17/2014
Hemispherx Biopharma (HEB) Announces New Publication With Potential Insight Into High Mortality Rate In Middle Eastern Respiratory Syndrome (MERS) 6/16/2014
H. Lundbeck A/S (LUN.CO) Release: New Study Shows That Brintellix® (Vortioxetine) Improves Cognitive Performance And Function In Adult Patients With Major Depression 6/16/2014
Chelsea Therapeutics, Inc. (CHTP) Presents Efficacy And Safety Data For NORTHERA At International Congress Of Parkinson's Disease And Movement Disorders 6/12/2014
Pfizer Inc. (PFE) To Showcase Over 10 Abstracts For XELJANZ® At Major Conference 6/11/2014
uniQure Announces Analysis Of Six-Year Follow-Up Data For Glybera® 6/3/2014
Boehringer Ingelheim Corporation Release: Antidote For Rapid Reversal Of Pradaxa® (Dabigatran Etexilate) Progresses Into Next Stage Of Clinical Investigation With Study In Patients 5/22/2014
The Medicines Company (MDCO) Release: Data On Angiox (Bivalirudin Injection) In Heart Attack Patients Presented At Europcr And Published In European Heart Journal 5/22/2014
GlaxoSmithKline (GSK) Touts Positive Incruse™-Ellipta®-Advair®-Diskus® Combo Data 5/20/2014
Dendreon Corporation (DNDN) Release: Treatment With PROVENGE® (Sipuleucel-T) Induces Antigen Spread Associated With Overall Survival Benefits In Advanced Prostate Cancer 5/20/2014
Biohit Release: Enrollment To Clinical Trials For Prevention Of Migraine-Type Headache 5/19/2014
Boehringer Ingelheim GmbH Release: New Study To Investigate Dabigatran Etexilate For Prevention Of Recurrent Stroke In High-Risk Patients 5/7/2014
Sucampo Pharmaceuticals, Inc. (SCMP) Announces New Data On AMITIZA And Opioid-Induced Constipation Published Online In Pain Medicine Journal 5/6/2014
Janssen Pharmaceutical Inc. Release: Landmark Study Shows Once-Monthly Long-Acting Therapy INVEGA® SUSTENNA® (Paliperidone Palmitate) Significantly Delayed Time To Relapse In Patients With Schizophrenia Compared To Daily Oral Antipsychotics 5/5/2014
Kowa Pharmaceuticals America Release: Data Showed After 52 Weeks, LIVALO® (Pitavastatin) 4 Mg Maintained Similar Safety And Significantly Greater LDL-C Reduction Compared With Pravastatin 40 Mg In HIV-Infected Adults With Dyslipidemia 5/1/2014
Repros Therapeutics Inc. (RPRX) Release: FDA Recommends Sperm Endpoints As Key Parameters For Assessment Of Androxal® Versus Approved Topical Gel 5/1/2014
Biogen Idec, Inc. (Massachusetts) (BIIB) Feels New Data Reinforce Efficacy Of TECFIDERA® (Dimethyl Fumarate) In MS Patients 4/30/2014
Biohit Starts Two Clinical Trials With Acetium® Capsule For Prevention Of Migraine-Type Headache 4/29/2014
Head-To-Head Study Reveals Novartis AG (NVS) Lung Drug Not Inferior To GlaxoSmithKline (GSK)'s Seretide 4/28/2014
AMAG Pharmaceuticals, Inc. (AMAG) Release: Study Showing Effectiveness Of Mugard® For Management Of Oral Mucositis Featured In The Journal Cancer 4/28/2014
Alexion Pharmaceuticals Inc. (ALXN) Initiates Multinational Registration Trials Of Eculizumab As A Potential Treatment For Patients With Relapsing Neuromyelitis Optica (NMO) And Refractory Generalized Myasthenia Gravis (MG) 4/24/2014
Cynapsus Therapeutics Announces Positive Results Of CTH-104 Clinical Study Of APL-130277 For Parkinson's Disease 4/24/2014
Saga Continues: Roche (RHHBY)'s Tamiflu No Better Than Tylenol At "Fighting Flu" 4/14/2014
Dendreon Corporation (DNDN) Release: Immune Responses Enhanced And Sustained When PROVENGE® (Sipuleucel-T) Is Given After Androgen Deprivation Therapy In Biochemically-Recurrent Prostate Cancer 4/11/2014
Gilead Sciences, Inc. (GILD)’s Sovaldi® Demonstrates Efficacy And Safety Among Chronic Hepatitis C Patients With Advanced Liver Disease 4/11/2014
FDA Grants Breakthrough Status Designation To Novartis AG (NVS)' Meningitis B Vaccine 4/8/2014
H. Lundbeck A/S (LUN.CO) Release: Treatment With Once-Monthly Abilify Maintena® (Aripiprazole) Significantly Reduces Hospitalisation Rates For Patients With Schizophrenia Compared With Daily Oral Antipsychotics 4/7/2014
Bristol-Myers Squibb Company (BMY)'s Eliquis® Works As Well As Pfizer Inc. (PFE)'s In Head-To-Head Subanalysis Study 3/27/2014
Roche (RHHBY)-Backed Study Finds Tamiflu Saved Lives In Flu Pandemic 3/19/2014
uniQure And Chiesi Farmaceutici SpA Announce Six Year Follow-up Data from Glybera® Treated Patients 3/17/2014
Pfizer Inc. (PFE) Vaccine Prevents Pneumonia In Landmark Study 3/14/2014
Merck & Co., Inc. (MRK) Release: New 96-Week ACTG Study Results Presented At CROI 2014; First Large Study Comparing ISENTRESS® (Raltegravir) Regimen To Two Protease Inhibitor Regimens In Previously Untreated Adults With HIV-1 3/5/2014
Janssen Pharmaceutica N.V. Release: New Data Show XEPLION® Significantly Delays Time To Relapse Compared To Treatment As Usual With Oral Antipsychotic Monotherapy 3/4/2014
Pfizer Inc. (PFE) Revs Up For Testing Of Over-The-Counter Lipitor 3/3/2014
Low-Level Usage Of Takeda Pharmaceutical Co. Ltd. (TKPYY)'s Actos May Still Hold Bladder Cancer Risk: Study 2/28/2014
Baxter International, Inc. (BAX) Presents Data At EAHAD From Long-Term Outcomes Registry Reinforcing Prophylaxis Treatment Experience With ADVATE 2/27/2014
Pfizer Inc. (PFE) Touts Positive Results In Pneumonia Vaccine Post-Approval Study 2/24/2014
Roche (RHHBY) May Share Avastin Brain Cancer Data Amid Conflicting Results 2/21/2014
Bristol-Myers Squibb Company (BMY) And Pfizer Inc. (PFE) Release: In a Subanalysis, Eliquis® (apixaban) Reduced The Risk of Stroke And Demonstrated Fewer Major Bleeding Events Versus Warfarin Consistently Across Age Groups, Including Older Patients With Nonvalvular Atrial Fibrillation 2/21/2014
Innovus Pharma To Exhibit Zestra® Its Clinically Proven Product For Female Sexual Arousal And Desire At The International Society For The Study Of Women's Sexual Health 2014 Annual Meeting In San Diego 2/20/2014
AMAG Pharmaceuticals, Inc. (AMAG) Release: Study Shows Mugard® Is More Effective Than Sham-Control At Reducing Mouth And Throat Soreness Associated With Oral Mucositis In Head And Neck Cancer Patients 2/18/2014
Actelion Ltd. (ALIOF.PK)'s Lung Drug May Face Study Against Gilead Sciences, Inc. (GILD) Rival 2/12/2014
Repros Therapeutics Inc. (RPRX) Reports Findings From The Six Month Study Of Androxal® In Men With Secondary Hypogonadism 2/10/2014
Galderma Pharma S.A. Announces The Publication Of Positive Results Of The Long-Term Study Of Mirvaso® Gel For Treatment Of Persistent Erythema Of Rosacea 1/29/2014
Ranbaxy Laboratories (RANBAXY.BO) Workers Fudged Test Results: FDA 1/28/2014
FDA Approved 188 Drugs Using One Single Study As Evidence 1/23/2014
Teva Pharmaceutical Industries Limited (TEVA) Release: Data Demonstrates Key Genes Respond Differently To COPAXONE® (glatiramer acetate injection) Versus A Purported Generic Glatiramer Acetate 1/13/2014
Alkermes plc (ALKS) Announces Advances With Its Late-Stage CNS Pipeline 1/8/2014
German Watchdog Deals Setback To Bayer AG (BAYN.DE) Eye Drug Eylea 1/6/2014
Popular ADHD Drugs May Cause Long Erections: FDA 12/18/2013
Osiris Therapeutics, Inc. (OSIR) Release: Journal Publishes Grafix® Clinical Study For Chronic Wounds 12/18/2013
Can The "Trust Hormone" Make It As A Treatment For Schizophrenia And Autism? 12/13/2013
Supernus Pharmaceuticals (SUPN) Posts Exciting Clinical Data Regarding Trokendi XR™ and Oxtellar XR™ on the Company Website 12/13/2013
AstraZeneca PLC (AZN)'s Arimidex Halves Breast Cancer Risk, Study Finds 12/12/2013
Lundbeck Inc. (LUN.CO) Release: New Study Showed Improvement In Cognitive Performance In Adult Patients Treated With Brintellix® (Vortioxetine) For Acute Episodes Of Major Depression 12/11/2013
Enzymotec Announces Publication Acceptance Of Clinical Study Results On Usage Of Vayacog® In Non-Demented Elderly 12/9/2013
Zealand Pharma  (ZEAL.CO) Informs That New Data Presented At The World Diabetes Congress Support Flexibility In Timing Of Administration For Lyxumia® 12/5/2013
Boehringer Ingelheim Corporation Release: New Study Showed Significant Reduction In Blood Glucose With Linagliptin Alone And In Combination With Metformin In Adults Newly Diagnosed With Type 2 Diabetes 12/3/2013
Janssen Pharmaceutica N.V. Unveils New Data On Xeplion® In Various Stages Of Schizophrenia 12/2/2013
Boehringer Ingelheim Corporation Release: Pradaxa® (Dabigatran Etexilate) 150mg Bid Continues To Be The Only Oral Anticoagulant Which Showed Superior Ischaemic Stroke Reduction Vs. Warfarin In Its Pivotal Study RE-LY® 11/25/2013
AstraZeneca PLC (AZN) Release: NHANES Analyses Reinforce The Need For Education To Help Increased Risk Dyslipidemic Patients Aggressively Treat Their Cholesterol 11/20/2013
Impressive Results From Ibrutinib Study Conducted At John Theurer Cancer Center Lead To FDA Approval Of Imbruvica As A Single Agent For Patients With Mantle Cell Lymphoma 11/19/2013
Boehringer Ingelheim Corporation Planning Two New Global Clinical Trials For Pradaxa® (Dabigatran Etexilate) In Expanded Patient Populations 11/19/2013
First Human Data Show Promise Of Boehringer Ingelheim Corporation’s Specific Antidote For Immediate, Complete And Sustained Reversal Of Pradaxa®-Induced Anticoagulation 11/18/2013
AstraZeneca PLC (AZN) Announces Initiation Of Two Additional Global Studies With Brilinta (Ticagrelor) 11/14/2013
ViroPharma Incorporated (VPHM) Release: Analysis Of Pivotal Study Data Showed Routine Prevention Of Hereditary Angioedema (HAE) Attacks With Cinryze® (C1 Esterase Inhibitor [Human]) Resulted In Improved Health-Related Quality Of Life Outcomes Compared To Acute Therapy With C1 Inhibitor While On Placebo 11/12/2013
EU Agency Questions AstraZeneca PLC (AZN) Over Heart Drug Trial 11/8/2013
Supernus Pharmaceuticals (SUPN) Announces Release of Exciting New Clinical Data on Trokendi XR™ 11/6/2013
Ibuprofen No Good in Treating Colds or Sore Throats, University of Southampton Study 11/5/2013
Sunovion Pharmaceuticals Inc. Announces Publication of Two Pivotal Studies Supporting FDA Approval of Latuda® (lurasidone HCl) as Monotherapy and Adjunctive Therapy in Adult Patients With Bipolar Depression in The American Journal of Psychiatry 11/1/2013
Newly Published Study Finds VIVUS, Inc. (VVUS)'s Qsymia Achieves Greater Weight Loss at Lower Doses Than Either of Its Components as Monotherapy 10/31/2013
Roche (RHHBY)'s Avastin Boosts Survival in Advanced Ovarian Cancer 10/23/2013
Pfizer Inc. (PFE) to Continue Developing Pain Therapeutics (PTIE)'s Painkiller Remoxy®; PTIE Stock Jumps 16.45% on Tuesday 10:44AM ET 10/22/2013
Ariad Pharmaceuticals, Inc. (ARIA) Stock Killed After FDA Places Trials of Inclusig on Hold; Stock Falls -65.99% at Market Close (October 9, 2013) 10/11/2013
VIVUS, Inc. (VVUS) Says Drug Delayed Progression to Diabetes 10/10/2013
Biogen Idec, Inc. (Massachusetts) (BIIB) Says Death of MS Patient Not Related to Drug 10/9/2013
Biogen Idec, Inc. (Massachusetts) (BIIB)'s Hot New MS Drug Tecfidera Maintains Efficacy in Long-Term Study 10/7/2013
Boehringer Ingelheim GmbH Release: Better Outcome in Case of Major Bleed for Patients Taking the Anticoagulant Pradaxa® Compared to Warfarin 10/7/2013
Teva Pharmaceutical Industries Limited (TEVA) to Present Further Results of Twenty-Year Open-Label Extension Study of Glatiramer Acetate 20 mg Daily for Relapsing-Remitting Multiple Sclerosis 10/4/2013
Biogen Idec, Inc. (Massachusetts) (BIIB) Release: New TYSABRI® Data Show Earlier Treatment and Longer-Term Use Result in Significant Reductions in MS Disease Activity 10/3/2013
Genzyme Corporation (GENZ) Release: Aubagio® Significantly Reduced Risk of New Clinical Relapse or MRI Lesion in Multiple Sclerosis Study 10/3/2013
Novo Nordisk A/S (NVO) Study Shows Tresiba Efficacy for Diabetes 9/26/2013
Data Show Sanofi (France) (SAN.PA)'s Lyxumia® Added to Basal Insulin Lowered Blood Sugar Especially When Fasting Plasma Glucose Was Controlled 9/24/2013
Pacira Pharmaceuticals, Inc. Release: Study Shows EXPAREL® Provided Improved Pain Control, Shorter Length of Hospital Stay and Substantial Cost Savings Following Total Knee Replacement 9/20/2013
Repros Therapeutics Inc. (RPRX) Reports Preliminary Findings: Second Pivotal Study and 6-Month Safety Study Support Androxal® Approvability 9/17/2013
Roche (RHHBY)'s Perjeta Works in Early-Stage Breast Cancer 9/11/2013
Boehringer Ingelheim Corporation, Pfizer Inc. (PFE) Encounter Conflicting Data on Safety of Spiriva 9/11/2013
FDA Probes Brain Infection in Patient on Novartis AG (NVS)'s MS Drug 9/3/2013
Boehringer Ingelheim Pharmaceuticals, Inc. Announces Plans to Expand Body of Evidence With Novel Cardiovascular Research Supporting Pradaxa® (dabigatran etexilate mesylate) 9/3/2013
AstraZeneca PLC (AZN), Bristol-Myers Squibb Company (BMY): New Diabetes Drug Onglyza Doesn't Raise Heart Attack Risk 9/3/2013
Boehringer Ingelheim GmbH's Respimat Inhaler Meets Safety Goal in Study 9/3/2013
Pfizer Inc. (PFE) Completes Pneumococcal Pneumonia Case Accrual For CAPiTA, Adult Vaccine Clinical Trial of Prevenar 13* 8/29/2013
Allergan Inc. (AGN) Demands the FDA Require Human Trials for Restasis Generics 8/22/2013
Novartis AG (NVS)'s Afinitor® Fails Phase 3 Liver Cancer Trial 8/8/2013
Orexo AB: First Patient Dosed in New Study on Long-Term Adherence to Treatment of Opioid Dependence With Zubsolv® 8/7/2013
Deja Vu: Second Probe Finds Manipulated Trial Data for Novartis AG (NVS) Drug 8/5/2013
New Retrospective Analysis on Galderma Laboratories’ Differin® Gel, 0.3% in Adult Female Acne Patients 8/1/2013
Celgene International Sárl (CELG) Release: Study of REVLIMID® (lenalidomide) in Patients with High-Risk Asymptomatic Smoldering Multiple Myeloma Published in The New England Journal of Medicine 8/1/2013
AstraZeneca PLC (AZN) Release: New Sub-Analysis of PLATO ACS Study Suggests Patient Types and Stent Types Had No Impact on Findings of Reduced Rate of Stent Thrombosis With BRILINTA (ticagrelor) 7/31/2013
European Medicines Agency Approves SmPC Change to Baxter International, Inc. (BAX)’s ADVATE to Include Information on PK-Guided Dosing Study 7/22/2013
Roche (RHHBY)'s Avastin as Good as Novartis AG (NVS)'s Lucentis for AMD 7/19/2013
Pacira Pharmaceuticals, Inc. Release: New Study Shows Significant Reduction in Opioids, Length of Hospital Stay and Cost of Care for Patients Receiving EXPAREL® as the Foundation of a Multimodal Postsurgical Pain Regimen 7/18/2013
Novartis AG (NVS) Drug Study Data Manipulated: Kyoto Prefectrual University of Medicine 7/16/2013
Boehringer Ingelheim Corporation Release: Benefits of Pradaxa® Maintained in Difficult to Treat Patients With Atrial Fibrillation and Symptomatic Heart Failure 7/16/2013
Celgene Corporation (CELG)'s Revlimid Improves Survival in Blood Cancer Patients 7/12/2013
Baxter International, Inc. (BAX) Presents ADVATE Data on Prophylaxis Management and Efficacy for Hemophilia A Patients 7/8/2013
Bristol-Myers Squibb Company (BMY), Pfizer Inc. (PFE)'s Eliquis Equal To Warfarin to Halt Blood Clots 7/2/2013
Merck & Co., Inc. (MRK) Release: FDA Approves New U.S. Labeling for ISENTRESS® (raltegravir) to Include 240-Week Results From STARTMRK Study of ISENTRESS Containing Regimen in Previously Untreated HIV-1 Infected Adult Patients 7/2/2013
Access Pharmaceuticals (ACCP) Announces Positive Top-Line Data From MuGard™ Phase IV Clinical Trial In Oral Mucositis Patients Presented At MASCC/ISOO 2013 Symposium 6/28/2013
Acorda Therapeutics (ACOR) Release: First Study of Diazepam Nasal Spray in People With Epilepsy Shows Feasibility of Dosing During Seizure 6/26/2013
A Bristol-Myers Squibb Company (BMY) and AstraZeneca PLC (AZN) Diabetes Trial is a "Dud" 6/24/2013
Merck & Co., Inc. (MRK) Release: New Analysis Shows That Patients With Type 2 Diabetes and Mild Renal Impairment Had Similar Improvement in Blood Sugar Control and Experienced Less Hypoglycemia With JANUVIA® (sitagliptin) Compared to Sulfonylurea 6/24/2013
VIVUS, Inc. (VVUS) Study Shows ED Drug Stendra Effective in 15 Minutes 6/19/2013
Kowa Pharmaceuticals America Release: New Data Showed LIVALO® (pitavastatin) 4 mg had Neutral Effects on Fasting Serum Glucose and HbA1c Levels in HIV-infected Adults with Dyslipidemia 6/17/2013
Celgene International Sárl (CELG) Oral Anti-Cancer Therapy REVLIMID® (lenalidomide) Now Indicated as a Treatment for Patients With Rare Form of Blood Disease 6/17/2013
Boehringer Ingelheim Corporation Release: New Long-Term Data Reinforce Safety Profile of Pradaxa® for Stroke Prevention in AF 6/17/2013
Novo Nordisk A/S (NVO) Release: Victoza® (Liraglutide [rDNA Origin] Injection) Safety Profile Further Supported at Scientific Workshop on Pancreatitis, Diabetes and Pancreatic Cancer 6/14/2013
Gilead Sciences, Inc. (GILD)'s Viread Reduces HIV Risk for Drug Users in Study 6/13/2013
AbbVie (ABBV) Presents First Study Assessing the Role of Predefined Doses of Methotrexate When Used in Combination With HUMIRA™ (adalimumab) for Rheumatoid Arthritis 6/13/2013
Merck & Co., Inc. (MRK) Joins Novo Nordisk A/S (NVO) to Reassure Safety of Diabetes Drugs 6/12/2013
Bristol-Myers Squibb Company (BMY)'s Orencia Matches Abbott Laboratories (ABT)' Humira in Arthritis Study 6/12/2013
Genmab A/S (GEN.CO) Release: Teprotumumab Restarts Clinical Development in New Indication 6/12/2013
Eisai Company, Ltd. (ESALY.PK) Confirms Therapeutic Effects of Lenvatinib in Patients With Melanoma in Strategic Collaboration With Quintiles, Inc. (Q) to Develop Eisai Anticancer Compounds 6/10/2013
Sanofi (France) (SAN.PA) Steps Up Diabetes Drive as Rivals Raise the Stakes 6/10/2013
OXiGENE (OXGN) Announces Publication of Final FACT Study Data in Journal Thyroid Suggest Survival Benefit of ZYBRESTAT® in Patients With Anaplastic Thyroid Cancer 6/10/2013
Alexion Pharmaceuticals Inc. (ALXN) Release: Soliris® Significantly Improved Clinical Outcomes in Patients With aHUS in Pivotal Trials Published in New England Journal of Medicine 6/6/2013
Rebellious FDA Reviewer Insists ARB Heart Drugs Have Cancer Risk 6/3/2013
New Bird Flu Found to be Resistant to Roche (RHHBY)'s Tamiflu 5/30/2013
Prometheus Laboratories Inc. Launches PROCLIVITY 02, a Phase IV Multi-Center Study Comparing the Sequence of Proleukin® (Aldesleukin for Injection) and Yervoy® (Ipilimumab) in Patients With Metastatic Melanoma 5/30/2013
Boehringer Ingelheim Corporation Release: New European Survey Highlights Ischaemic Stroke Protection as Treatment Priority for Patients With Atrial Fibrillation 5/28/2013
Positive Trial Results for Otsuka Pharmaceutical Co., Ltd. and H. Lundbeck A/S (LUN.CO)'s Abilify Maintena in Schizophrenia 5/22/2013
"Love Hormone" Promises Safer Births After Pfizer Inc. (PFE) Flop 5/21/2013
Otsuka Pharmaceutical Co., Ltd. and H. Lundbeck A/S (LUN.CO): Study Shows Effects of Treatment With ABILIFY MAINTENA#0153; (Aripiprazole) on Psychiatric Hospitalization Rates for Patients With Schizophrenia1 5/21/2013
Sunovion Pharmaceuticals Inc. Presents Data Showing 12 Months of Latuda® (lurasidone HCl) Treatment Resulted in Higher Remission Rates in Adult Patients With Schizophrenia Compared to Seroquel XR® (quetiapine XR) 5/21/2013
Sunovion Pharmaceuticals Inc. Presents Results From a One-year, Large Simple Safety Study of BROVANA® (arformoterol tartrate) Inhalation Solution 5/20/2013



//-->